Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effects of Potassium Canrenoate and Trometamol on Blood Flow in Brain-Dead Organ Donors

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on evaluating the effects of a medication called potassium canrenoate on individuals who are brain-dead and are potential organ donors. The study aims to understand how this medication affects the heart and blood circulation in these individuals. Potassium canrenoate is administered as a solution for injection, and it is compared to a placebo to assess its impact.

The trial involves participants who are brain-dead and are candidates for organ donation, specifically for kidney or multiple organ harvesting. During the study, participants will receive either potassium canrenoate or a placebo, and their heart and blood circulation will be monitored to see how they respond to the treatment. The study will also use a solution called sodium chloride as part of the infusion process.

The purpose of this study is to gather information on the safety and effectiveness of potassium canrenoate in maintaining stable heart and blood circulation in brain-dead organ donors. The results will help determine if this medication can improve the conditions for organ donation and potentially benefit recipients of these organs. The study will continue to monitor the health of organ recipients for several years after the transplant to assess long-term outcomes.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after meeting specific criteria, including age and medical condition requirements.

    Consent is obtained from a designated support person or family member.

  2. Step 2

    Randomization

    Participants are randomly assigned to receive either potassium canrenoate or a placebo.

    This process ensures unbiased results in evaluating the effects of the medication.

  3. Step 3

    Medication administration

    The medication, potassium canrenoate, is administered intravenously as a solution for injection.

    A sodium chloride solution is also used for infusion during the trial.

  4. Step 4

    Monitoring and evaluation

    Participants are closely monitored for changes in hemodynamics, which refers to the blood flow and circulation within the body.

    The primary focus is on the impact of the medication on the cardiovascular system before organ removal.

  5. Step 5

    Data collection

    Data is collected on various outcomes, including the occurrence of cardio circulatory arrest and the ability to perform organ removal.

    Additional data includes the average hourly dose of noradrenaline/adrenaline and the volume of fluids used.

  6. Step 6

    Follow-up

    Secondary objectives are assessed by reviewing data from the CRISTAL database.

    This includes evaluating the health status of kidney recipients at intervals of 3 months, 1 year, 3 years, and 10 years post-transplant.

Who can join the trial?

7 criteria

  • Men and women who are **18 years or older**.
  • Individuals who have been diagnosed with **encephalic death**. This means the brain has stopped functioning, confirmed by either two tests showing no brain activity or a special brain scan showing no blood flow in certain brain areas.
  • Individuals from whom one or both **kidneys** are planned to be taken for donation, following the current procedures.
  • The dose of **vasopressor agent** (a medicine that helps maintain blood pressure) should not have changed by more than 1 mg per hour in the hour before joining the study, and the dose should be less than 7 mg per hour at the time of joining.
  • The patient should be **euvolemic** at the time of joining, meaning they have a normal amount of body fluids.
  • The patient must be **affiliated with a Social Security scheme**.
  • A **signed written consent** must be provided by a support person or a family member, as required by the regulations.

Who cannot join the trial?

5 criteria

  • Individuals who are not **brain-dead**. This means the person must have no brain activity and be declared brain-dead.
  • Individuals who are not candidates for **organ donation**. This means the person must be considered for donating organs like kidneys.
  • Individuals who are not within the specified **age range**. The study is only for certain age groups.
  • Individuals who do not meet the **gender requirements**. Both males and females are eligible, but specific criteria may apply.
  • Individuals who are not part of a **vulnerable population**. This refers to groups that may need special protection or consideration.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

  • Responsive

    CHRU De Nancy

    FranceVandoeuvre Les Nancy, France

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Potassium Canrenoate is a medication being studied for its effects on the heart and blood circulation in individuals who are brain-dead and potential organ donors. The trial aims to understand how this medication might help maintain stable blood flow and heart function in these individuals, which is important for the success of organ donation.

What is already known about the treatment

Potassium Canrenoate – Potassium canrenoate is administered intravenously and is currently being studied in clinical trials for its effects on hemodynamics in brain-dead organ donors. It is not yet widely used in standard medical practice, but it is being evaluated for its potential benefits in organ donation settings. The main therapeutic indication being explored is its ability to stabilize blood pressure and circulation in brain-dead individuals who are candidates for organ donation. At the molecular level, potassium canrenoate works by blocking aldosterone receptors, which helps in reducing fluid retention and improving heart function. It is classified pharmacologically as a diuretic and an aldosterone antagonist.

Investigated diseases

Brain Death – Brain death is a condition where there is a complete and irreversible loss of brain function, including the brainstem. It is considered a legal definition of death in many jurisdictions. The condition occurs when the brain is deprived of oxygen for an extended period, leading to the cessation of all neurological activity. Despite the heart continuing to beat with mechanical support, the individual cannot breathe independently. Brain death is distinct from a coma or vegetative state, as there is no possibility of recovery. It is often a consideration in organ donation, as the body can be maintained on life support for organ preservation.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-513809-31-00Protocol code2019PI117Estimated enrolment36 patientsSponsorCHRU De Nancy

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).